AbbVie is gaining investor confidence as its new immunology drugs Skyrizi and Rinvoq show strong revenue growth, offsetting declines from older products like Humira. The company raised its full-year earnings forecast after beating revenue expectations, supported by a robust pipeline and significant R&D investments. Despite risks from patent expirations and past financial leverage, AbbVie’s consistent dividend increases and strong margins make it a compelling long-term investment. Recent market volatility offers buying opportunities for investors focused on steady income and growth potential.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
